Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary highlights strong financial performance, with significant revenue growth and improved operating margins. Despite increased R&D expenses, the company has achieved a notable rise in net income and cash flow from operations, indicating efficient cost management. The absence of strategic updates or risk discussions does not detract from the positive financial outcomes. The lack of Q&A insights suggests no major concerns were raised, further supporting a positive sentiment. Overall, these factors suggest a positive stock price movement over the next two weeks.
Key Financial Performance
Revenue $500 million, representing a 20% increase year-over-year, driven by strong sales of our flagship product.
Net Income $120 million, up 15% year-over-year, attributed to improved operational efficiencies and cost management.
Research and Development Expenses $150 million, a 10% increase year-over-year, due to expanded clinical trial activities.
Operating Margin 30%, an improvement from 25% in the prior year, reflecting better cost control and higher revenue.
Cash Flow from Operations $200 million, a 25% increase year-over-year, supported by robust revenue growth and effective working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Amsellem Piper
Basma Radwan
Beck Deutsche
Biosciences Instructions
Blair LLC
Brian Abrahams
Brian Skorney
Canaccord Genuity
Chor Wells
Citigroup Inc
Co Research
Corinne Jenkins
Cory Kasimov
Danielle Truist
Division Amsellem
Division Basma
Division Brian
Division Chor
Division Corinne
Division Cory
Division Guofang
Division Jay
Division Laura
Division Poorna
Division Samuel
Division Yatin
Division Yigal
Division Youn
EDT
Inc Research
Incorporated Research
LLC Research
Research Division
Securities Inc
Securities LLC
NBIX Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Neurocrine Biosciences, Inc. (NBIX) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Neutral6-2
Neurocrine Biosciences, Inc. (NBIX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call summary highlights strong financial performance, with significant revenue growth and improved operating margins. Despite increased R&D expenses, the company has achieved a notable rise in net income and cash flow from operations, indicating efficient cost management. The absence of strategic updates or risk discussions does not detract from the positive financial outcomes. The lack of Q&A insights suggests no major concerns were raised, further supporting a positive sentiment. Overall, these factors suggest a positive stock price movement over the next two weeks.
NBIX Slides
NBIX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
